Q2 2026 results

Committed to solid profitable growth

August 5, 2026

Forward looking and intended use statements

Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Regulation G: In this presentation, QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. Adjusted results include adjusted net sales, adjusted gross income, adjusted net income, adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted operating income margin, adjusted net income before taxes, adjusted income tax, adjusted tax rate, adjusted EBITDA, adjusted EPS, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

Q2 2026: Solid performance exceeding outlook

QIAGEN

Growth

Q2 2026 net sales ahead of outlook with growth pillars driving performance

- 0% CER, ahead of the outlook for ~-2% CER decline
- Sales from growth pillars increased 5% CER, led by Sample tech, QIAcuity and QDI
- QuantiFERON grew 1% CER, with solid trends outside immigration testing

Profitability

Improvements in adj. diluted EPS and sequential margin expansion

- **Margin:** 29.4% adj. operating income margin vs. 29.9% in Q2 2025, while investing in future growth
- **Adj. diluted EPS:** $0.62 CER ahead of outlook for ≥$0.60 CER
- **Very strong operating cash flow[(1)]:** $301 mn in H1 2026 while investing in efficiency programs and higher inventory levels

Outlook

2026: Reaffirming net sales and adjusted diluted EPS outlook

- Net sales: ~+1-2% CER driven by expansion from pillars
- Adjusted diluted EPS: ≥$2.43 CER

Net sales	**$535 mn** ($531 mn CER)	**0% CER** vs. Q2 2025
Adj. diluted EPS	**$0.62** ($0.62 CER)	**+3%** vs. Q2 2025
Adj. operating margin	**29.4%**	**Q1 2026: 27.4%**
Operating cash flow	**H1: $301 mn**	Strong cash generation

CER – Constant exchange rates | (1) Including about $20 million of cash out from efficiency programs.

Q2 2026: Sales performance and key developments

Sales by product group
(In $ millions at actual rates)



Key developments

Sample technologies
- +9% CER growth, +3% CER growth excl. Parse
- Automated consumables delivered high teens CER growth

QuantiFERON
- +1% CER growth with solid trends outside immigration testing
- Growth across core testing groups offset immigration weakness

QIAstat-Dx
- -7% CER decline against a strong respiratory comparison
- Growing demand for the GI and Meningitis panels

QIAcuity
- Double-digit CER growth on continued consumables demand
- Continued adoption across research and clinical applications

QDI
- Solid single-digit CER growth led by clinical applications
- Advancing AI capabilities through strategic partnerships

(1) Q2: Net sales $531 million CER (0% at constant exchange rates, 0% at actual rates)
CER – Constant exchange rates

Q2 2026: Portfolio developments

Sample technologies:
Expanding automated sample preparation

Progressing rollout of new automation systems

- **QIAsymphony Connect:** Commercial launch of new IVD-compliant system
- **QIAsprint Connect:** First instrument placements with very positive feedback
- **QIAmini**: On track for launch in Fall 2026



QIAGEN Digital Insights:
Accelerating biomedical research

NVIDIA collaboration to advance AI capabilities

- **Knowledge bases:** Combining QDI content with NVIDIA BioNeMo
- **Research:** Supporting target identification and biomarker discovery

QIAstat-Dx:
Advancing syndromic testing solutions

Launch of QIAstat-Dx panels and expansion into new testing areas

- **Bloodstream infections:** Portfolio expansion with BCID GPF Plus AMR panel (Europe)
- **Cyclospora outbreak:** Supporting U.S. response with the GI panel

Q3 and FY 2026: Outlook and assumptions

(As of August 5, 2026)	Q3 2026 outlook	FY 2026 outlook
Net sales	**~+1-2% CER**	**~+1-2% CER**
Anticipated currency impact[1]	Negative impact of ~-1 ppt	Positive impact of ~+1 ppt
Adjusted diluted EPS[2]	**≥$0.62 CER**	**≥$2.43 CER**
Anticipated currency impact[1]	Neutral	Neutral
Adjustments to operating income (In $ millions):		
Business integration and acquisition-related items	~$5 mn	~$15 mn
Restructuring-related items	~$10 mn	~$55 mn
Amortization of acquired intellectual property	~$15 mn	~$62 mn
Adjusted tax rate (%)	**~17-18%**	**~17-18%**
Weighted average number of diluted shares outstanding (Based on $43.00 share price)	**~208 million**	**~209 million**

(1) Based on exchange rates as of August 3, 2026.

(2) QIAGEN reports adjusted results to provide additional insight into its performance. Adjusted results are non-GAAP financial measures that QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of ongoing core operations, vary significantly from period to period, or affect the comparability of results with competitors and its own prior periods. Furthermore, QIAGEN uses non-GAAP and constant currency financial measures internally in planning, forecasting and reporting, as well as to measure and compensate employees. QIAGEN also uses adjusted results when comparing current performance to historical operating results, which have consistently been presented on an adjusted basis.

QIAGEN

Appendix

2026 sales outlook: H1 vs. H2 updated perspectives



Multiple levers to improve sales trends in H2 2026

CER – Constant exchange rates I ppts – Percentage points I (1) QIAstat-Dx and QIAcuity launches

Disciplined capital allocation to drive long-term value

Organic investments	**Profitable targeted investments** into growth pillars and digitization to fuel profitable business expansion
Focused M&A	**Value-creating transactions** to enhance portfolio and maintain leadership
Shareholder returns	**>$1.1 bn returned to shareholders** through synthetic share buybacks and dividends since 2024

Annual dividend

- Dividend approval at the AGM in June 2026
- $0.35 dividend per share (~$72 mn payment in July 2026)

Share repurchase

- Additional shareholder authorization secured for share repurchases over the next 18 months

Q2 2026: Consolidated Statements of Income (unaudited)

QIAGEN

(In $ thousands, except share data)	Three months ended June 30, 2026	Three months ended June 30, 2025
Net sales	**535,040**	**533,540**
Cost of sales:		
Cost of sales	181,973	185,951
Acquisition-related intangible amortization	12,681	13,303
Total cost of sales	**194,654**	**199,254**
Gross profit	**340,386**	**334,286**
Operating expenses:		
Sales and marketing	116,675	118,097
Research and development	50,429	47,750
General and administrative	30,093	30,648
Acquisition-related intangible amortization	2,339	1,817
Restructuring, acquisition, integration and other, net	8,449	14,072
Total operating expenses	**207,985**	**212,384**
Income from operations	**132,401**	**121,902**
Adjusted income from operations	*157,059*	*159,503*
Other income (expense):		
Interest income	9,361	13,859
Interest expense	(10,022)	(7,605)
Other income (expense), net	365	(1,335)
Total other (expense) income, net	**(296)**	**4,919**
Income before income tax expense	**132,105**	**126,821**
Adjusted income before income tax expense	*157,082*	*164,506*
Income tax expense	**28,704**	**30,571**
Adjusted income tax expense	*27,877*	*32,587*
Net income	**103,401**	**96,250**
Adjusted net income	*129,205*	*131,919*
Diluted earnings per share	**$0.50**	**$0.44**
Adjusted diluted earnings per share	*$0.62*	*$0.60*
Shares used in computing diluted earnings per share (in thousands)	**207,828**	**218,183**

H1 2026: Consolidated Statements of Income (unaudited)

(In $ thousands, except share data)	Six months ended June 30, 2026	Six months ended June 30, 2025
Net sales	**1,027,360**	**1,016,996**
Cost of sales:		
Cost of sales	351,432	347,245
Acquisition-related intangible amortization	25,939	26,784
Total cost of sales	**377,371**	**374,029**
Gross profit	**649,989**	**642,967**
Operating expenses:		
Sales and marketing	231,281	224,431
Research and development	98,690	91,533
General and administrative	57,875	62,256
Acquisition-related intangible amortization	4,667	3,610
Restructuring, acquisition, integration and other, net	40,650	23,888
Total operating expenses	**433,163**	**405,718**
Income from operations	**216,826**	**237,249**
Adjusted income from operations	*291,793*	*303,700*
Other income (expense):		
Interest income	19,923	29,249
Interest expense	(21,073)	(14,899)
Other income (expense), net	2,258	(5,229)
Total other income, net	**1,108**	**9,121**
Income before income tax expense	**217,934**	**246,370**
Adjusted income before income tax expense	*293,583*	*315,390*
Income tax expense	**46,490**	**59,362**
Adjusted income tax expense	*51,788*	*62,447*
Net income	**171,444**	**187,008**
Adjusted net income	*241,795*	*252,943*
Diluted earnings per share	**$0.82**	**$0.85**
Adjusted diluted earnings per share	*$1.16*	*$1.15*
Shares used in computing diluted earnings per share (in thousands)	**208,953**	**219,186**

2026: Quarterly sales by product group

(In $ millions at actual rates / change in actual, CER rates)	Q1 2026			Q2 2026			Q3 2026			Q4 2026			FY 2026		
	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER
Sample technologies	170	13%	9%	182	9%	9%							352	11%	9%
Diagnostic solutions(1)	185	-1%	-4%	204	-1%	-2%							389	-1%	-3%
Of which QuantiFERON	*113*	*-3%*	*-5%*	*131*	*2%*	*1%*							*244*	*0%*	*-2%*
Of which QIAstat-Dx	*36*	*4%*	*-1%*	*32*	*-6%*	*-7%*							*68*	*-1%*	*-4%*
Of which NeuMoDx	—	*-100%*	*-100%*	—	*-100%*	*-100%*							—	*-100%*	*-100%*
Of which Other	*36*	*19%*	*15%*	*40*	*1%*	*0%*							*77*	*8%*	*7%*
PCR/Nucleic acid amplification	69	-9%	-13%	74	-7%	-8%							143	-8%	-11%
Genomics/NGS	57	6%	4%	61	3%	2%							117	5%	3%
Other	12	-31%	-31%	15	-34%	-34%							27	-32%	-33%
Total	**492**	**2%**	**-1%**	**535**	**0%**	**0%**							**1,027**	**1%**	**-1%**

(1) Includes QIAcuity digital PCR Dx revenues in 2026 (Q2: $5 million; H1: $8 million). QIAcuity is split between Diagnostic solutions and PCR / Nucleic acid amplification.
Tables may contain rounding differences. | Percentage changes are to prior-year periods.

2026: Quarterly sales by product type and region

(In $ millions at actual rates / change in actual, CER rates)	Q1 2026			Q2 2026			Q3 2026			Q4 2026			FY 2026		
	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER
Product type															
Consumables and related revenues	445	2%	-1%	484	2%	1%							928	2%	0%
Instruments	48	-2%	-6%	52	-10%	-11%							99	-6%	-8%
Geographic region(1)															
Americas	249	-2%	-2%	285	2%	1%							535	0%	0%
Europe / Middle East / Africa	173	8%	0%	178	-1%	-2%							351	3%	-1%
Asia-Pacific / Japan	70	2%	0%	72	-2%	-2%							142	0%	-1%
Total	**492**	**2%**	**-1%**	**535**	**0%**	**0%**							**1,027**	**1%**	**-1%**

(1) Rest of World contributed less than 1% of net sales in Q1, Q2 and H1 2026. | Tables may contain rounding differences.

Q2 and H1 2026: Reconciliation to adjusted results (unaudited)

(In $ millions, except EPS)	Net sales	Gross profit	Operating income	Pre-tax income	Income tax	Tax rate	Net income	Diluted EPS*
Second quarter 2026								
Reported results	535.0	340.4	132.4	132.1	(28.7)	22 %	103.4	0.50
Adjustments								
Business integration, acquisition and restructuring related items (a)		1.2	9.6	9.6	(2.7)		6.9	0.03
Purchased intangibles amortization (b)		12.6	15.0	15.0	(3.7)		11.3	0.05
Non-cash other income, net				0.3	(0.1)		0.2	0.00
Certain income tax items (c)					7.4		7.4	0.04
Total adjustments		13.9	24.7	25.0	0.8		25.8	0.12
Adjusted results	**535.0**	**354.3**	**157.1**	**157.1**	**(27.9)**	**18 %**	**129.2**	**0.62**
First half 2026								
Reported results	1,027.4	650.0	216.8	217.9	(46.5)	21 %	171.4	0.82
Adjustments								
Business integration, acquisition and restructuring related items (a)		3.7	44.3	44.3	(12.6)		31.7	0.15
Purchased intangibles amortization (b)		25.9	30.6	30.6	(7.6)		23.0	0.11
Non-cash other income, net				0.7	(0.2)		0.5	0.00
Certain income tax items (c)					15.1		15.1	0.07
Total adjustments		29.6	75.0	75.7	(5.3)		70.4	0.34
Adjusted results	**1,027.4**	**679.6**	**291.8**	**293.6**	**(51.8)**	**18 %**	**241.8**	**1.16**

Please see footnotes for these tables on the following page.

* Weighted number of diluted shares (Q2 2026: 207.8 million; H1 2026: 209.0 million)

Q2 and H1 2026: Footnotes for reconciliation to adjusted results (unaudited)

(a) Includes costs incurred in connection with streamlining operations and improving overall efficiency as well as costs related to various contemplated and completed acquisition projects including subsequent integration activities at GNX Data Systems, Ltd. (Genoox) and Parse Biosciences (Parse).

(b) Adjustment includes the amortization of Genoox and Parse intangible assets acquired in Q2 2025 and Q4 2025, respectively.

(c) These items represent updates in QIAGEN's assessment of ongoing examinations or other tax items that are not indicative of the Company's normal future income tax expense.

Tables may contain rounding differences.

2026: Quarterly income statement summary

(In $ millions, unless indicated) (Diluted EPS in $ per share)	Q1 2026	Q2 2026	Q3 2026	Q4 2026	FY 2026
Net sales	492.3	535.0			1,027.4
Net sales (CER)	476.7	531.1			1,007.9
Gross profit	309.6	340.4			650.0
Gross profit margin	*62.9%*	*63.6%*			*63.3%*
Adjusted gross profit	325.4	354.3			679.6
Adjusted gross profit margin	*66.1%*	*66.2%*			*66.2%*
Operating income	84.4	132.4			216.8
Operating margin	*17.1%*	*24.7%*			*21.1%*
Adjusted operating income	134.7	157.1			291.8
Adjusted operating margin	*27.4%*	*29.4%*			*28.4%*
Tax rate	21%	22%			21%
Adjusted tax rate	18%	18%			18%
Net income	68.0	103.4			171.4
Adjusted net income	112.6	129.2			241.8
Diluted EPS	0.33	0.50			0.82
Adjusted diluted EPS (CER) ($ per share)	0.54 (0.54)	0.62 (0.62)			1.16 (1.15)
Diluted shares outstanding for EPS calculation	208.9	207.8			209.0

CER - Constant exchange rates | Table may have rounding differences. | Refer to accompanying tables for reconciliation of reported to adjusted figures.

Consolidated Balance Sheets

(In $ thousands, except par value)	June 30, 2026	December 31, 2025
Assets	(unaudited)	
Cash and cash equivalents	768,500	839,005
Short-term investments	25,000	259,913
Accounts receivable, net	389,850	402,608
Inventories, net	311,355	301,888
Prepaid expenses and other current assets	161,922	191,659
Total current assets	**1,656,627**	**1,995,073**
Property, plant and equipment, net	923,043	923,948
Goodwill	2,693,398	2,700,658
Intangible assets, net	352,347	386,431
Other long-term assets	263,787	275,122
Total long-term assets	**4,232,575**	**4,286,159**
Total assets	**5,889,202**	**6,281,232**

(In $ thousands, except par value)	June 30, 2026	December 31, 2025
Liabilities and equity	(unaudited)	
Current portion of long-term debt	16,517	—
Accrued and other current liabilities	485,846	439,481
Accounts payable	79,083	72,656
Total current liabilities	**581,446**	**512,137**
Long-term debt	1,627,105	1,654,428
Other long-term liabilities	322,911	336,513
Total long-term liabilities	**1,950,016**	**1,990,941**
Common shares, EUR 0.01 par value: Authorized – 410,000 shares Issued – 206,801 shares (2026) and 217,685 shares (2025)	2,404	2,529
Additional paid-in capital	956,239	1,436,360
Retained earnings	2,814,982	2,748,390
Accumulated other comprehensive loss	(402,667)	(377,309)
Less treasury shares at cost – 306 shares (2026) and 764 shares (2025)	(13,218)	(31,816)
Total equity	**3,357,740**	**3,778,154**
Total liabilities and equity	**5,889,202**	**6,281,232**

Balance sheet data and metrics		
Group liquidity(1)	793,500	1,098,918
Net debt(2)	850,122	555,510
Leverage ratio(3)	1.1x	0.7x

(1) Group liquidity includes cash, cash equivalents and short-term investments.
(2) Net debt is equal to total outstanding long-term debt minus group liquidity.
(3) Leverage ratio is calculated on trailing four quarters as net debt / adjusted EBITDA.

Consolidated Statements of Cash Flows (unaudited)

QIAGEN

Six months ended (In $ thousands)	June 30, 2026	June 30, 2025
Cash flows from operating activities:		
Net income	171,444	187,008
Adjustments to reconcile net income to net cash provided by operating activities, net of effects of businesses acquired:		
Depreciation and amortization	101,766	93,386
Non-cash impairments	15,218	2,537
Amortization of debt discount and issuance costs	1,180	1,124
Share-based compensation	16,618	23,096
Deferred tax (benefit) expense	(3,317)	3,175
Loss on marketable securities	—	968
Other items, net including fair value changes in derivatives	1,615	8,615
Change in operating assets, net	(17,550)	(19,934)
Change in operating liabilities, net	14,345	1,200
Net cash provided by operating activities	**301,319**	**301,175**
Cash flows from investing activities:		
Purchases of property, plant and equipment	(89,813)	(84,092)
Purchases of intangible assets	(2,034)	(1,008)
Purchases of short-term investments	(25,000)	(134,720)
Proceeds from redemptions of short-term investments	259,294	402,057
Cash paid for acquisitions, net of cash acquired	(1,864)	(66,595)
Cash received (paid) for collateral asset	1,257	(36,046)
Purchases of investments, net	(626)	(1,512)
Net cash provided by investing activities	**141,214**	**78,084**

Six months ended (In $ thousands)	June 30, 2026	June 30, 2025
Cash flows from financing activities:		
Capital repayment	(496,749)	(280,086)
Tax withholdings related to vesting of stock awards	(13,945)	(15,227)
Cash received (paid) for collateral liability	1,117	(9,940)
Cash paid for contingent consideration	(2,000)	(9,219)
Other financing activities	(552)	(226)
Net cash used in financing activities	**(512,129)**	**(314,698)**
Effect of exchange rate changes on cash and cash equivalents	(909)	5,699
Net (decrease) increase in cash and cash equivalents	**(70,505)**	**70,260**
Cash and cash equivalents, beginning of period	839,005	663,555
Cash and cash equivalents, end of period	**768,500**	**733,815**
Reconciliation of Free Cash Flow[(1)]		
Net cash provided by operating activities	301,319	301,175
Purchases of property, plant and equipment	(89,813)	(84,092)
Free Cash Flow	**211,506**	**217,083**

(1) Free cash flow is a non-GAAP financial measure and is calculated from net cash provided by operating activities reduced by purchases of property, plant and equipment.

Q2 and H1 2026: Currency impact

	Net sales (In $ millions / Actual)	Net sales (CER)	Currency exposure (As % of CER sales)	Change (In $ millions)
Q2 2026				
U.S. dollar	309.4	309.4	58%	0.0
Euro	99.0	96.9	18%	-2.1
British pound	17.8	17.7	3%	-0.1
Japanese yen	9.2	10.2	2%	1.0
Other currencies	99.6	96.9	18%	-2.7
Total net sales	**535.0**	**531.1**	100%	**-3.9**
H1 2026				
U.S. dollar	582.4	582.4	58%	0.0
Euro	196.1	184.6	18%	-11.5
British pound	36.5	35.0	3%	-1.5
Japanese yen	21.0	22.3	2%	1.3
Other currencies	191.4	183.6	18%	-7.8
Total net sales	**1,027.4**	**1,007.9**	100%	**-19.5**

CER - Constant exchange rates | Table may have rounding differences.
Other currencies include CAD, DKK, TRY, SEK, CHF, AUD, BRL, CNY, MYR, SGD, KRW, HKD, MXN, ILS, INR, TWD, SAR, THB and ZAR.

Employees as of June 30, 2026

QIAGEN

	Americas	Europe / Middle East / Africa	Asia Pacific / Japan / ROW	Total Q2 2026	Total Q1 2026	Change
Production	287	1,070	140	1,497	1,513	-1%
R&D	158	730	51	939	956	-2%
Sales	549	811	694	2,054	2,060	0%
Marketing	77	167	65	309	320	-3%
Administration	72	437	156	665	677	-2%
Total	**1,143**	**3,215**	**1,106**	**5,464**	**5,526**	-1%

Your contacts

QIAGEN

Daniel Wendorff
Vice President
Head of Investor Relations

Phone: +49 2103 29 11322
E-mail: daniel.wendorff@qiagen.com

Dr. Domenica Martorana
Associate Director
Investor Relations

Phone: +49 2103 29 11244
E-mail: domenica.martorana@qiagen.com

Alexandra Koenig
Coordinator
Investor Relations

Phone: +49 2103 29 11709
E-mail: alexandra.koenig@qiagen.com

Calendar

Q3 2026 results	November 2026
Q4 2026 results	February 2027

Share information

NYSE:	QGEN
Frankfurt:	QIA
ISIN / CUSIP:	NL0015002SN0 / N72482 156
WKN:	A41HBE

E-mail:
ir@qiagen.com

Internet:
corporate.QIAGEN.com

QGEN
LISTED
NYSE

DAX

TecDAX

www.linkedin.com/company/qiagen

www.x.com/QIAGEN

www.facebook.com/QIAGEN

www.youtube.com/user/QIAGENvideos